Verrica Pharmaceuticals (NASDAQ:VRCA): Investor Relations Program

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica is focused on innovation, changing the narrative around viral skin diseases, and making treatment a more efficient process for both physicians and patients.

Verrica Pharmaceuticals has been a LifeSci client since December 2022. As part of the strategy to raise the Company’s visibility amongst global investors, LifeSci scheduled multiple Non-Deal Roadshows with top-tier institutions as well as organized and hosted an in-person High-Net-Worth and family-office investor event for Verrica in New York City. The event created a great opportunity for Verrica to showcase its technologies in the dermatology health space, and its potential to reshape and transform the skin disease landscape.

• Targeted outreach and marketing in the weeks leading up to the event to selected HNWI, family-offices, and sell-side analysts & bankers
• Over 20+ Buyside Attendees took part in the event on June 7th, 2023
• The LifeSci team worked with management to highlight Verrica Pharmaceuticals upcoming milestones: VP-102 currently under FDA review, which could potentially be the first product approved by the FDA to treat molluscum contagiosum (molluscum) a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children

LifeSci, on behalf of Verrica Pharmaceuticals, successfully arranged NDR’s with new institutional and high-net-worth investors across the US from December 2022 to July 2023. This resulted in an appreciation of 122.64% from $3.18, to $7.08 over the nine-month period.